论文部分内容阅读
目的分析慢性阻塞性肺疾病和支气管哮喘患吸入布地奈德/福莫特罗的肺功能变化趋势,为临床治疗效果评价提供理论依据。方法选择该院2013年6月—2014年6月接诊的50例慢性阻塞性肺疾病和50例支气管哮喘患者作为研究对象,所有患者均雾化吸入布地奈德/福莫特罗(信必可都保)治疗,吸入后0、5、10、20、30min使用全自动肺功能检测仪监测肺功能指标变化(FEV1、FEV1/预计值%、FVC、IC、FEF25%、FEF50%、FEF75%)。结果哮喘组和COPD组治疗后5、10、20、30min的FEV1、FVC、FEV1/预计值、IC、FEF25%、FEF50%、FEF75%均较治疗前明显升高,呈进行性增加趋势。结论慢性阻塞性肺疾病和支气管哮喘吸入布地奈德/福莫特罗后均能有效改善肺功能,肺功能指标均呈进行性增加趋势,但两种疾病吸入后肺通气改善速度存在差异,哮喘患者的肺功能改善程度明显优于COPD患者。
Objective To analyze the changes of pulmonary function of inhaled budesonide and formoterol in patients with chronic obstructive pulmonary disease and bronchial asthma and to provide a theoretical basis for the evaluation of the clinical therapeutic effect. Methods 50 patients with chronic obstructive pulmonary disease and 50 patients with bronchial asthma admitted from June 2013 to June 2014 in our hospital were enrolled in this study. All patients received inhaled budesonide / formoterol Can be protected) treatment, inhaled 0,5,10,20,30 min after the use of automatic lung function test instrument to monitor changes in lung function indicators (FEV1, FEV1 / predicted value, FVC, IC, FEF25%, FEF50%, FEF75% ). Results The FEV1, FVC, FEV1 / IC50, FEF50%, FEF75% at 5, 10, 20 and 30 minutes after treatment in asthma group and COPD group were significantly higher than those before treatment, showing a trend of progressive increase. Conclusions Chronic obstructive pulmonary disease and bronchial asthma inhaled budesonide / formoterol can effectively improve lung function, pulmonary function indicators showed a trend of progressive increase, but the two diseases after inhalation of pulmonary ventilation to improve the speed difference, asthma Patients improved lung function significantly better than COPD patients.